A Staphylococcus aureus mouse keratitis topical infection model: Cytokine balance in different strains of mice

Immunology and Cell Biology

Volumn 83, Issue 3, 2005, Pages 294-300

  Hume, Emma B H ^a,b   Cole, Nerida ^a,b   Khan, Shamila ^b   Garthwaite, Linda L ^a   Aliwarga, Yulina ^b   Schubert, Tracey L ^b   Willcox, Mark D P ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BRIEN HOLDEN VISION INSTITUTE   (Australia)

Author keywords

Chemokine; Cytokine; Inflammatory response; Microbial keratitis; Staphylococcus aureus

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; BLINDNESS; CONTROLLED STUDY; CORNEA INJURY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DISEASE RESISTANCE; ENUCLEATION; IMMUNE RESPONSE; INFLAMMATION; KERATITIS; MOUSE; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS STRAIN 38; STAPHYLOCOCCUS AUREUS STRAIN 8325 4; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; TH2 CELL; TREATMENT OUTCOME;

ANIMALS; CELL COUNT; CHEMOKINES; CHEMOKINES, CXC; CYTOKINES; DISEASE MODELS, ANIMAL; EYE; KERATITIS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTROPHILS; PHOSPHOLIPASE C; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE;

POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 20444412338     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01326.x     Document Type: Article

References (38)

1. Asbell P, Stenson S. Ulcerative keratitis: 30 years' laboratory experience. Arch. Ophthalmol. 1982; 100: 77-80.
2. Gudmundsson OG, Omerod L, Kenyon KR et al. Factors influencing predilection and outcome in bacterial keratitis. Cornea 1989; 8: 115-21.
3. Kruz OA, Sabir SM, Capo H, Alfonso E. Microbial keratitis in childhood. Ophthalmology 1993; 100: 192-6.
4. Wang AG, Wu CC, Liu JH. Bacterial corneal ulcers: a multivariate study. Ophthalmologica 1998; 212: 216-32.
5. O'Callaghan RJ, Callegan MC, Moreau JM et al. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect. Immun. 1997; 65: 1571-8.
6. Rudd JC, Moshifar M. Methicillin resistant Staphylococcus aureus keratitis after laser in situ keratomileusis. J. Cataract Refract. Surg. 2001; 27: 471-3.
7. Kantzanou M, Tassios PT, Tseleni-Kotsovili A, Legakis NJ, Vatopoulos AC. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 1999; 43: 729-31.
8. Balaban N, Collins V, Cullor JS et al. Prevention of S. aureus infections by the peptide RIP. Peptides 2000; 21: 1301-11.
9. Dajcs JJ, Hume EBH, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest. Ophthalmol. Vis. Sci. 2000; 41: 1432-7.
10. Hume EBH, Moreau JM, Conerly LL et al. Clarithromycin for experimental Staphylococcus aureus keratitis. Curr. Eye Res. 1999; 18: 358-62.
11. Hume EBH, Dajcs JJ, Moreau JM, O'Callaghan RJ. Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect. Immun. 2000; 68: 6052-5.
12. O'Callaghan RJ, Engel LS, Hill JM. The rabbit intrastromal injection model of bacterial keratitis. In: Zak O, Sande M (eds) Handbook of Animal Models of Infection. London: Academic Press, 1999: 367-74.
13. Hume EBH, Dajcs JJ, Moreau JM et al. Staphylococcus corneal virulence in a new topical model of infection. Invest. Ophthalmol. Vis. Sci. 2001; 42: 2904-908.
14. Girgis DO, Sloop GD, Reed JM, O'Callaghan RJ. A new topical model of Staphylococcus corneal infection in the mouse. Invest. Ophthalmol. Vis. Sci. 2003; 44: 1591-7.
15. Hazlett LD, McClellan S, Kwon B, Barrett R. Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive. Invest. Ophthalmol. Vis. Sci. 2000; 41: 805-810.
16. Hazlett LD, Rudner XL, McClellan SA, Barrett RP, Lighvani S. Role of IL-12 and IFN-gamma in Pseudomonas aeruginosa corneal infection. Invest. Ophthalmol. Vis. Sci. 2002; 43: 419-24.
17. Kernacki KA, Berk RS. Characterization of the inflammatory response induced by corneal infection with Pseudomonas aeruginosa. J. Ocul Pharmacol. 1994; 10: 281-8.
18. Cole N, Bao S, Willcox MDP, Husband AJ. Expression of interleukin-6 in the cornea in response to infection with different strains of Pseudomonas aeruginosa. Infect. Immun. 1999; 67: 2497-502.
19. Cole N, Krockenberger M, Stapleton F et al. Experimental Pseudomonas aeruginosa keratitis in interleukin-10 gene knockout mice. Infect. Immun. 2003; 71: 1328-36.
20. Kernacki KA, Goebel DJ, Poosch MS, Hazlett LD. Early cytokine and chemokine gene expression during Pseudomonas aeruginosa corneal infection in mice. Infect. Immun. 1998; 66: 376-9.
21. Guillen C, McInnes IB, Vaughan DM et al. Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J. Immunol. 2002; 168: 3950-57.
22. Haziot A, Hijiya N, Schultz K, Zhang F, Gangloff SC, Goyert SM. CD14 plays no major role in shock induced by Staphylococcus aureus but down-regulates TNF-alpha production. J. Immunol. 1999; 162: 4801-805.
23. Sinha P, Ghosh AK, Das T, G Ray PK. Protein A of Staphylococcus aureus evokes Th1 type response in mice. Immunol. Lett. 1999; 67: 157-65.
24. Yao L Berman JW Factor SM Lowy FD. Correlation of histopathologic and bacteriologic changes with cytokine expression in an experimental murine model of bacteremic Staphylococcus aureus infection. Infect. Immun. 1997; 65: 3889-95.
25. Cole N Bao S Stapleton F et al. Pseudomonas aeruginosa keratitis in IL-6 deficient mice. Int. Arch. Allergy Immunol. 2003; 130: 165-72.
26. Araki-Sasaki K, Ohashi Y, Sasabi T et al. An SV40 immortalized human corneal epithelial cell line and its characterization. Invest. Ophthalmol. Vis. Sci. 1995; 36: 614-21.
27. Yao L, Bengualid V, Lowy FD, Gibbons JJ, Hatcher VB, Berman JW. Internalization of Staphylococcus aureus by endothelial cells induces cytokine gene expression. Infect. Immun. 1995; 63: 1835-9.
28. Xue ML, Thakur A, Willcox MDP, Zhu H, Lloyd AR, Wakefield D. Role and regulation of CXC-chemokines in acute experimental keratitis. Exp. Eye Res. 2003; 76: 221-31.
29. Kielian T, Barry B, Hickey WF. CXC chemokine receptor-2 ligands are required for neutrophil-mediated host defense in experimental brain abscesses. J. Immunol. 2001; 166: 634-43.
30. Kernacki KA, Barrett RP, Hobden JA, Hazlett LD. Macrophage inflammatory protein-2 is a mediator of polymorphonuclear neutrophil influx in ocular bacterial infection. J. Immunol. 2000; 164: 1037-45.
31. Coates NJ, McColl SR. Production of chemokines in vivo in response to microbial stimulation. J. Immunol. 2001; 166: 5176-82.
32. Lee SW, Hong YS, Chun CM et al. Anti-inflammatory effects of IL-4 and IL-10 on human polymorphonuclear leukocytes. J. Korean Med. Sci. 2002; 17: 7-14.
33. Matsui K, Mishikawa A. Lipoteichoic acid from Staphylococcus aureus induces Th-2-prone dermatitis in mice sensitized percutaneously with an allergan. Clin. Exp. Allergy 2002; 32: 783-8.
34. Sasaki S, Nishikawa S, Miura T et al. Interleukin-4 and interleukin-10 are involved in host resistance to Staphylococcus aureus infection through regulation of gamma interferon. Infect. Immun. 2000; 68: 2424-30.
35. Barton BE, Shortall J, Jackson JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect. Immun. 1996; 64: 714-18.
36. Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 2002; 39: 531-6.
37. Wilson M, Seymour R, Henderson B. Bacterial perturbation of cytokine networks. Infect. Immun. 1998; 66: 2401-409.
38. Bamberger DM, Herndon BL, Fitch J, Florkowski A, Parkhurst V. Effects of neutrophils on cefazolin activity and penicillin-binding proteins in Staphylococcus aureus abscesses. Antimicrob. Agents Chemother. 2002; 46: 2878-84.